NCT03292302View on ClinicalTrials.gov

Phase 1 Study of ELX-02 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 26, 2017

Primary Completion Date

December 15, 2017

Study Completion Date

December 15, 2017

Conditions
Genetic DiseaseNonsense Mutation
Interventions
DRUG

Placebo

Placebo comparator

DRUG

ELX-02

Synthetic aminoglycoside

Trial Locations (1)

Unknown

SGS Life Sciences, Clinical Pharmacology Unit, Antwerp

Sponsors
All Listed Sponsors
collaborator

SGS Life Sciences, a division of SGS Belgium NV

OTHER

lead

Eloxx Pharmaceuticals, Inc.

INDUSTRY

NCT03292302 - Phase 1 Study of ELX-02 in Healthy Adults | Biotech Hunter | Biotech Hunter